Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Status:
Withdrawn
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate
the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of
hospitalized adults with cUTI or AP.